• Filana Therapeutics outlined plan to develop simufilam for tuberous sclerosis complex-related epilepsy, positioning drug as potential first-in-class oral filamin A modulator.
• Program remains on FDA clinical hold following December 2025 letter; work underway to address requests for additional preclinical data and protocol modifications ahead of a response.
• Preclinical package cited anti-seizure activity across two mouse models, including 60% reduction in seizure frequency in Yale RhebCA model.
• Company highlighted safety database of more than 2,000 prior simufilam-treated subjects, with some exposed up to 24 months.
• Method-of-treatment patent issued in 2025 was in-licensed from Yale; product supply described as in place for planned proof-of-concept study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Filana Therapeutics Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.